Ticker Symbol: TOS/TSX
Shares Outstanding: 47,863,402
<p><location>QUEBEC</location> CITY, <chron>Oct. 29</chron> /CNW Telbec/ - TSO3 Inc. ("TSO3") (TSX: TOS) announced today that it will report Financial Results for the Third Quarter 2009 ended <chron>September 30, 2009</chron> and will update on negotiations with 3M on <chron>Wednesday, November 11, 2009</chron>. TSO3 will host a Conference Call and a Webcast at <chron>10:30 A.M. (EST</chron>) the same day.</p>
<p>Analysts and Institutional Investors are invited to participate to the call. The numbers to dial for access are 514-807-8791 (Montréal area), 416-915-5762 (<location>Toronto</location> area) or the Toll-Free number 1-800-590-1508. Journalists and other interested parties may listen to the live Webcast of the Conference Call accessible via TSO3's Website at: <a href="http://www.tso3.com/en/investors/financial-reports-webcasts.php">http://www.tso3.com/en/investors/financial-reports-webcasts.php</a>. The Webcast will be archived for 90 days.</p>
<p>TSO3, founded in Québec City in 1998, specializes in the research and development of innovative, high-performance medical instrument sterilization technology with high commercial potential. The Company's first product, the TSO3 STERIZONE(R) 125L Sterilizer, is designed for sterile processing centers in the hospital environment. The Company believes that its technology represents an advantageous replacement solution to other low temperature sterilization processes currently used in hospitals.</p>
<p>In contrast to other methods, the ozone sterilization process developed and patented by TSO3 combines attributes that answer market needs for: efficacy, costs savings, increased safety for patients and hospital staff, and a "green" environmentally safe process.</p>
<p>The TSO3 STERIZONE(R) 125L Sterilizer is cleared for commercialization by the US and Canadian regulatory agencies for sterilization of metal and heat sensitive instruments, as well as for devices with diffusion-restricted spaces, such as rigid endoscopes having a single stainless steel channel. In 2009, the Company received clearance from Health <location>Canada</location> for sterilization of additional complex medical instruments, including multi-channel flexible endoscopes.</p>
<p>For more information about TSO3, visit the Company's Web site at <a href="http://www.tso3.com">www.tso3.com</a></p>
<p>The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of any financing undertaken by TSO3) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other risks and uncertainties.</p>
The TSX has neither approved nor disapproved the information contained
herein and accepts no responsibility for it.
For further information: For further information: Caroline Côté, Director, Corporate Communications and Investor Relations, (418) 651-0003, Ext. 237, email@example.com; Source: TSO3 Inc.